RxSight (NASDAQ:RXST) PT Raised to $54.00 at Stifel Nicolaus

RxSight (NASDAQ:RXSTFree Report) had its target price increased by Stifel Nicolaus from $45.00 to $54.00 in a research note published on Monday morning, Benzinga reports. The firm currently has a buy rating on the stock.

RXST has been the subject of several other reports. Wells Fargo & Company raised shares of RxSight from an equal weight rating to an overweight rating and increased their target price for the stock from $31.00 to $42.00 in a report on Wednesday, December 13th. Needham & Company LLC increased their price objective on shares of RxSight from $35.00 to $41.00 and gave the company a buy rating in a report on Monday, January 8th. Morgan Stanley assumed coverage on shares of RxSight in a report on Monday, December 4th. They set an overweight rating and a $36.00 price objective for the company. Finally, Oppenheimer increased their price objective on shares of RxSight from $50.00 to $54.00 and gave the company an outperform rating in a report on Monday, January 29th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, RxSight currently has an average rating of Buy and a consensus price target of $39.38.

View Our Latest Stock Report on RxSight

RxSight Price Performance

RxSight stock opened at $50.83 on Monday. The firm has a 50 day moving average of $42.66 and a 200 day moving average of $32.92. RxSight has a 12-month low of $12.77 and a 12-month high of $51.15.

Insider Buying and Selling at RxSight

In related news, insider Eric Weinberg sold 1,285 shares of the firm’s stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $40.00, for a total value of $51,400.00. Following the completion of the transaction, the insider now directly owns 339,978 shares of the company’s stock, valued at $13,599,120. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, insider Eric Weinberg sold 1,285 shares of the firm’s stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $40.00, for a total value of $51,400.00. Following the completion of the transaction, the insider now directly owns 339,978 shares of the company’s stock, valued at $13,599,120. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, COO Ilya Goldshleger sold 10,365 shares of the firm’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $50.74, for a total transaction of $525,920.10. Following the completion of the transaction, the chief operating officer now directly owns 26,475 shares of the company’s stock, valued at $1,343,341.50. The disclosure for this sale can be found here. Insiders sold a total of 514,795 shares of company stock valued at $20,373,660 in the last three months. 21.13% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of RXST. RiverPark Advisors LLC grew its holdings in shares of RxSight by 70.0% in the fourth quarter. RiverPark Advisors LLC now owns 668 shares of the company’s stock valued at $27,000 after purchasing an additional 275 shares in the last quarter. Steward Partners Investment Advisory LLC bought a new stake in RxSight in the fourth quarter worth $27,000. BluePath Capital Management LLC bought a new stake in RxSight in the third quarter worth $32,000. IFP Advisors Inc bought a new stake in RxSight in the second quarter worth $62,000. Finally, UBS Group AG lifted its position in RxSight by 413.6% in the fourth quarter. UBS Group AG now owns 5,388 shares of the company’s stock worth $68,000 after buying an additional 4,339 shares during the last quarter. 66.51% of the stock is owned by hedge funds and other institutional investors.

RxSight Company Profile

(Get Free Report)

RxSight, Inc, an ophthalmic medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.

Featured Articles

Analyst Recommendations for RxSight (NASDAQ:RXST)

Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.